Eli Lilly bridge program targets Medicare patients, shares near record territory on NYSE

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-26, 14:43.

Eli Lilly & Co. (US5324571083) is drawing attention on the NYSE as it prepares a Medicare GLP-1 Bridge Program for its obesity portfolio targeting US seniors, according to recent company and market reports. MarketScreener news overview The program comes while Eli Lilly shares trade above 1,120 US dollars on the NYSE, close to their all-time high levels.

Medicare bridge program for GLP-1 drugs

On 26 June 2026, a news summary based on company statements reported that Eli Lilly will make its GLP-1 drugs Zepbound and Foundayo available via a Medicare GLP-1 Bridge Program, with a fixed patient price per month. Börse Global analysis of the Medicare program The bridge initiative is expected to start in July 2026 and targets Medicare beneficiaries, a patient group that has previously had limited access to obesity medications.

According to this analysis, eligible patients under the bridge construct will pay a fixed amount of about 50 US dollars per month for Eli Lilly’s GLP-1 obesity treatments, independent of list prices. Börse Global analysis of the Medicare program The concept is designed to secure early market share in the US senior segment before broader, regular Medicare coverage for obesity drugs is established.

Analyst focus and S&P 500 positioning

Eli Lilly belongs to the S&P 500 and has become a core obesity and diabetes exposure for many US-focused portfolios, trading under the ticker LLY on the NYSE. MarketBeat overview on Eli Lilly MarketBeat data show the stock closed at around 1,127.62 US dollars on 25 June 2026, up roughly 0.9 percent on the day, with a market capitalization near 1.06 trillion US dollars.

Research house Leerink Partners recently adjusted its view and lifted its price target for Eli Lilly shares from 1,119 to 1,232 US dollars while maintaining an Outperform rating, according to a 25 June 2026 note summarized by financial portals. MarketScreener summary of the Leerink Partners update This keeps the consensus tone constructive as investors weigh the incremental revenue potential from the Medicare bridge initiative.

How Eli Lilly earns its money

Eli Lilly generates its revenue primarily from innovative prescription medicines in areas such as diabetes, obesity, immunology, oncology and neuroscience, with GLP-1 therapies like Zepbound and diabetes drug Mounjaro currently among the key growth drivers. Company overview of Lilly products These products complement established brands such as Trulicity in diabetes and Verzenio in oncology, creating a diversified but obesity-skewed earnings profile.

Where Eli Lilly shares trade today

The Eli Lilly shares (US5324571083) trade on 2026-06-25 at 16:00 Eastern Time on the NYSE at 1,130.27 US dollars, based on delayed quote data from financial portals.

This text is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any financial instrument. Values and dates are based on publicly available sources and may change.